Method of treating lower urinary tract disorders

• US 20050020577A1
• Filed: 06/07/2004
• Published: 01/27/2005
• Est. Priority Date: 04/04/2003
• Status: Abandoned Application

• Current Assignee: Dynogen Incorporated
• Original Assignee: Dynogen Incorporated
• Inventors: Landau, Steven B., Fraser, Matthew O., Miller, Cheryl L.
• Application Number:
  US10/863,771
• Publication Number:
  US 20050020577A1
• Time in Patent Office: Days
• US Class Current: 514/218
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/551 having two nitrogen atoms, e.g. dilazep
• CPC Class Codes: A61K 31/5513 1,4-Benzodiazepines, e.g. diazepam or clozapine
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 13/02 of urine or of the urinary tract, e.g. urine acidifiers
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 13/10 of the bladder
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT₃ receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5-HT₃ antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.

Claims

1-70. -70. (canceled)

71. A method of treating overactive bladder comprising administering a compound of formula I:

72. The method of claim 71, wherein said as-needed basis is from about 0 minutes to about 10 hours prior to commencement of an activity wherein suppression of overactive bladder is desired.

73. The method of claim 71, wherein said as-needed basis is from about 0 minutes to about 5 hours prior to commencement of an activity wherein suppression of overactive bladder is desired.

74. The method of claim 71, wherein said as-needed basis is from about 0 minutes to about 3 hours prior to commencement of an activity wherein suppression of overactive bladder is desired.

75. The method of claim 71, wherein said as-needed basis is about 10 minutes, about 20 minutes, about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, or about 10 hours prior to commencement of an activity wherein suppression of overactive bladder is desired.

76. A method of treating overactive bladder comprising administering a compound of formula II:

77. The method of claim 76, wherein said as-needed basis is from about 0 minutes to about 10 hours prior to commencement of an activity wherein suppression of overactive bladder is desired.

78. The method of claim 76, wherein said as-needed basis is from about 0 minutes to about 5 hours prior to commencement of an activity wherein suppression of overactive bladder is desired.

79. The method of claim 76, wherein said as-needed basis is from about 0 minutes to about 3 hours prior to commencement of an activity wherein suppression of overactive bladder is desired.

80. The method of claim 76, wherein said as-needed basis is about 10 minutes, about 20 minutes, about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, or about 10 hours prior to commencement of an activity wherein suppression of overactive bladder is desired.

81. A method of treating a lower urinary tract disorder comprising administering a compound of formula I:

82. The method of claim 81, wherein said as-needed basis is from about 0 minutes to about 10 hours prior to commencement of an activity wherein treatment of a lower urinary tract disorder is desired.

83. The method of claim 81, wherein said as-needed basis is from about 0 minutes to about 5 hours prior to commencement of an activity wherein treatment of a lower urinary tract disorder is desired.

84. The method of claim 81, wherein said as-needed basis is from about 0 minutes to about 3 hours prior to commencement of an activity wherein treatment of a lower urinary tract disorder is desired.

85. The method of claim 81, wherein said as-needed basis is about 10 minutes, about 20 minutes, about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, or about 10 hours prior to commencement of an activity wherein treatment of a lower urinary tract disorder is desired.

86. A method of treating a lower urinary tract disorder comprising administering a compound of formula II:

87. The method of claim 86, wherein said as-needed basis is from about 0 minutes to about 10 hours prior to commencement of an activity wherein treatment of a lower urinary tract disorder is desired.

88. The method of claim 86, wherein said as-needed basis is from about 0 minutes to about 5 hours prior to commencement of an activity wherein treatment of a lower urinary tract disorder is desired.

89. The method of claim 86, wherein said as-needed basis is from about 0 minutes to about 3 hours prior to commencement of an activity wherein treatment of a lower urinary tract disorder is desired.

90. The method of claim 86, wherein said as-needed basis is about 10 minutes, about 20 minutes, about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, or about 10 hours prior to commencement of an activity wherein treatment of a lower urinary tract disorder is desired.

91. Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine or a salt thereof for the manufacture of a medicament for the treatment of urinary incontinence.

92. Use according to claim 91, wherein the salt is the monohydrate hydrochloride.

93. Use according to claim 91 or claim 92, wherein the urinary incontinence is stress urinary incontinence.

94. A method for the treatment of urinary incontinence in a patient suffering therefrom, comprising administering to the patient an effective amount of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine or a salt thereof.

95. The method according to claim 94, wherein the salt is the monohydrate hydrochloride.

96. The method according to claim 94 or claim 95, wherein the urinary incontinence is stress urinary incontinence.